Senores Pharmaceuticals Invests USD 2 Million in US Subsidiary in Rights Issue

Mumbai, 19 September 2025: Senores Pharmaceuticals Limited (BSE: 544319, NSE: SENORES) has announced that it has made an investment of USD 1.99 million in its wholly owned US subsidiary, Senores Pharmaceuticals Inc. (SPI), via a rights issue. The move supports the company’s IPO commitments and is aimed at strengthening the working capital base of its American subsidiary.

Headquartered in Ahmedabad, Senores Pharmaceuticals deals in pharmaceutical formulation development and marketing. Listed on both BSE and NSE, the US subsidiary SPI is the hub around which Senores’ global plans revolve. SPI holds key intellectual property, manages drug approval processes, and anchors Senores’ partnerships with global distributors and promotion agencies.

Senores Pharmaceuticals Invests USD 1.99 Million in US Subsidiary to Fund Growth Needs

The latest rights issue involves the acquisition of 120,480 equity shares for each at USD 16.60, generating nearly USD 2 million in cash for SPI. Senores will still continue to own 100% of the subsidiary, though, after the infusion of new capital. The capital injection follows the company’s plan to utilize IPO proceeds for foreign expansion and retain ownership of intellectual property (IP) for ANDA (Abbreviated New Drug Application) approvals.

US Subsidiary Turnover More Than Triples to USD 11.4 Million in FY25

SPI, incorporated in January 2021, has demonstrated significant financial momentum. Its turnover expanded from USD 3.35 million in FY23 to USD 5.93 million in FY24, before more than doubling again to USD 11.41 million in FY25. This strong trajectory highlights both increased demand in the US market and SPI’s successful engagement with global marketing partners.

Senores Pharmaceuticals Share Price Increases After Announcement

Following the investment announcement, Senores Pharmaceuticals Ltd (NSE: SENORES) share price increased marginally. The stock opened at ₹717.40 on 19 September 2025 and traded at ₹718.55 at 9:41 am IST, up by ₹2.40 or 0.34%. The scrip recorded a high of ₹722.70 and a low of ₹714.80 during the early trading session and had a market capitalisation of ₹3,300 crore. The modest gain is a testament to market attention on the company’s pioneering move to fortify its foreign business.

Alignment with IPO Aims and US Market Expansion Fuels Optimism

The capital allocation is a part of Senores’ IPO strategy, where it has set aside funds for its US subsidiary to ensure robust working capital and IP management. Keeping SPI capitalised at full capitalisation benefits the company in safeguarding its ANDA pipeline while leveraging partnerships to achieve market entry. The financial growth of SPI, along with this assistance through funding, underpins Senores’ strategy of expanding globally while maintaining regulatory and contractual obligations.

Senores Pharmaceuticals’ recent funding of approximately USD 2 million in its US subsidiary demonstrates the company’s commitment to consolidating foreign operations while pursuing IPO plans. Steady turnover of SPI demonstrates its increasing role in the company’s growth, targeting the US market as a major pillar in Senores’ long-term business journey.

REF: https://nsearchives.nseindia.com/corporate/SENORES_18092025155750_Intimationregardingrightissuesigned.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations